Gilead Sciences, Inc. (BMV:GILD)

Market Cap	2.71T
Revenue (ttm)	533.52B
Net Income (ttm)	148.76B
Shares Out	n/a
EPS (ttm)	117.81
PE Ratio	18.22
Forward PE	14.45
Dividend	59.68 (2.74%)
Ex-Dividend Date	Dec 15, 2025

Volume	293
Average Volume	762
Open	2,189.46
Previous Close	2,181.64
Day's Range	2,189.46 - 2,189.46
52-Week Range	1,874.30 - 2,347.00
Beta	0.35
RSI	48.27
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD